9:57
iwNHL 2018 | Cellular therapy and drug access for viral lymphomas
Catherine Bollard et al.
8:24
iwNHL 2018 | Viral lymphomas: risk factors and treatments
Catherine Bollard et al.
3:00
SOHO 2018 | Promising therapeutic developments for Hodgkin lymphoma
Stephen Ansell
2:30
SOHO 2018 | MRD in lymphoma
Stephen Ansell
2:19
SOHO 2018 | CAR T-cell therapy in B-cell malignancies
Stephen Ansell
2:30
SOHO 2018 | Brentuximan vedotin for treating Hodgkin Lymphoma
Stephen Ansell
1:39
EBMT 2018 | Current landscape and future prospects for Hodgkin lymphoma treatment
Martin Hutchings
2:36
BSH 2018 | Hodgkin lymphoma: difficulties faced in geriatrics
Wendy Osborne
1:54
ASH 2017 | Promising results for venetoclax across multiple hematological malignancies
Giovanni Martinelli
2:18
EHA 2018 | Novel drug combinations for Hodgkin lymphoma: more effective & less toxic
Anna Sureda
1:14
BSH 2018 | Checkmate 205 study results: nivolumab in classical Hodgkin Lymphoma
Graham Collins
1:11
BSH 2018 | Hodgkin lymphoma: when autologous transplant is unsuccessful
Stephen Robinson
4:15
EHA 2018 | Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
1:57
EHA 2018 | Biomarkers in lymphoma
Arjan Diepstra
3:31
EHA 2018 | Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
Ramon Garcia-Sanz
2:22
EBMT 2018 | Novel therapies in minimizing transplant complications
Mohamad Mohty
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals